Simon Mark Walker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5148269/publications.pdf

Version: 2024-02-01

60 papers

1,738 citations

³⁶¹⁴¹³
20
h-index

289244 40 g-index

64 all docs

64
docs citations

64 times ranked 3086 citing authors

#	Article	IF	CITATIONS
1	Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making. Medical Decision Making, 2022, 42, 17-27.	2.4	8
2	A randomized controlled trial of a proportionate universal parenting program delivery model (E-SEE) Tj ETQq0 0 (O rgBT /Ov	erlock 10 Tf 5
3	A proportionate, universal parenting programme to enhance social-emotional well-being in infants and toddlers in England: the E-SEE Steps RCT. Public Health Research, 2022, 10, 1-162.	1.3	2
4	The cost-effectiveness of a proportionate parenting programme for primary caregivers and their child: an economic evaluation using evidence from the E-SEE Trial. BMC Health Services Research, 2022, 22, .	2.2	3
5	Cost-Effectiveness of Cardiovascular Magnetic Resonance in Diagnosing Coronary Artery Disease in the Australian Health Care System. Heart Lung and Circulation, 2021, 30, 380-387.	0.4	15
6	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. Heart, 2021, 107, 381-388.	2.9	12
7	Costâ€effectiveness analysis of public health interventions with impacts on health and criminal justice: An applied crossâ€sectoral analysis of an alcohol misuse intervention. Health Economics (United) Tj ETQq1 1 0.7	848 1 4 rg	BT \$ Overlock 1
8	Responding to Health-Improving but Cost-Ineffective Care. JAMA Health Forum, 2021, 2, e210229.	2,2	0
9	Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies. Pharmacoeconomics, 2021, 39, 879-887.	3.3	6
10	Enhancing Social-Emotional Outcomes in Early Years (E-SEE): Randomized Pilot Study of Incredible Years Infant and Toddler Programs. Journal of Child and Family Studies, 2021, 30, 1933-1949.	1.3	5
11	Uncertainty Analysis in Intervention Impact on Health Inequality for Resource Allocation Decisions. Medical Decision Making, 2021, 41, 653-666.	2.4	3
12	Non-invasive imaging software to assess the functional significance of coronary stenoses: a systematic review and economic evaluation. Health Technology Assessment, 2021, 25, 1-230.	2.8	2
13	Cost-effectiveness of point-of-care creatinine testing to assess kidney function prior to contrast-enhanced computed tomography imaging. European Journal of Radiology, 2021, 142, 109872.	2.6	O
14	Hearing dogs for people with severe and profound hearing loss: a wait-list design randomised controlled trial investigating their effectiveness and cost-effectiveness. Trials, 2021, 22, 700.	1.6	3
15	Impact of Socioeconomic Differences on Distributional Cost-effectiveness Analysis. Medical Decision Making, 2020, 40, 606-618.	2.4	6
16	The costâ€effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa. Journal of the International AIDS Society, 2020, 23, e25469.	3.0	0
17	The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing theÂaddition of Proactive Psychological Medicine to usual care, with usual care alone, on the Âtime spent in hospital by older acute hospital inpatients. Trials, 2020, 21, 373.	1.6	3
18	Stress CMR Imaging for StableÂChestÂPainÂSyndromes. JACC: Cardiovascular Imaging, 2020, 13, 1518-1520.	5.3	5

#	Article	IF	CITATIONS
19	Methods to promote equity in health resource allocation in low- and middle-income countries: an overview. Globalization and Health, 2020, 16, 6.	4.9	23
20	Distributional cost effectiveness analysis of West Yorkshire low emission zone policies. Health Economics (United Kingdom), 2020, 29, 567-579.	1.7	7
21	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation. Health Technology Assessment, 2020, 24, 1-248.	2.8	12
22	Effectiveness and Cost-Effectiveness of Receiving a Hearing Dog on Mental Well-Being and Health in People With Hearing Loss: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15452.	1.0	1
23	The HOME Study: study protocol for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients. Trials, 2019, 20, 483.	1.6	13
24	Cost-effectiveness of a national quality improvement programme to improve survival after emergency abdominal surgery: Learning from 15,856 patients. International Journal of Surgery, 2019, 72, 25-31.	2.7	5
25	Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers. Applied Health Economics and Health Policy, 2019, 17, 577-590.	2.1	73
26	A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities. Cost Effectiveness and Resource Allocation, 2019, 17, 7.	1.5	9
27	An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. Pharmacoeconomics, 2019, 37, 631-643.	3.3	33
28	Reply letter to: "A commentary on "cost-effectiveness of a national quality improvement programme to improve survival after emergency abdominal surgery, health economic evaluation―(int J Surg 2019;) Tj ETQc	0 № rgB ⁻	「/@verlock 10
29	A national quality improvement programme to improve survival after emergency abdominal surgery: the EPOCH stepped-wedge cluster RCT. Health Services and Delivery Research, 2019, 7, 1-96.	1.4	9
30	Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. PharmacoEconomics - Open, 2018, 2, 403-413.	1.8	7
31	Five year trends (2008–2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. Europace, 2018, 20, 643-653.	1.7	20
32	Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment. Medical Decision Making, 2018, 38, 495-508.	2.4	14
33	Modelling the cost-effectiveness of pay-for-performance in primary care in the UK. BMC Medicine, 2018, 16, 135.	5. 5	22
34	Reflecting the real value of health care resources in modelling and cost-effectiveness studiesâ€"The example of viral load informed differentiated care. PLoS ONE, 2018, 13, e0190283.	2.5	16
35	Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation. Health Technology Assessment, 2018, 22, 1-260.	2.8	6
36	Enhancing Social-Emotional Health and Wellbeing in the Early Years (E-SEE): a study protocol of a community-based randomised controlled trial with process and economic evaluations of the incredible years infant and toddler parenting programmes, delivered in a proportionate universal model. BMJ Open, 2018, 8, e026906.	1.9	8

#	Article	IF	Citations
37	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. Medical Decision Making, 2017, 37, 148-161.	2.4	18
38	Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. New England Journal of Medicine, 2017, 377, 233-245.	27.0	156
39	Impact of missed treatment opportunities on outcomes in hospitalised patients with heart failure. Open Heart, 2017, 4, e000726.	2.3	2
40	Who bears the cost of NICE public health recommendations?. British Medical Bulletin, 2017, 124, 1-8.	6.9	1
41	Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial. Pharmacoeconomics, 2016, 34, 795-804.	3.3	9
42	Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 125-140.	4.0	49
43	Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates. JAMA - Journal of the American Medical Association, 2016, 316, 1051.	7.4	227
44	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 2016, 19, 138-144.	0.3	24
45	Cost-effectiveness of functional cardiac imaging in the diagnostic work-up of coronary heart disease. European Heart Journal Quality of Care & Dutcomes, 2016, 2, 201-207.	4.0	27
46	Using electronic health records to predict costs and outcomes in stable coronary artery disease. Heart, 2016, 102, 755-762.	2.9	26
47	Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities. Pharmacoeconomics, 2016, 34, 155-160.	3.3	16
48	The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technology Assessment, 2016, 20, 1-158.	2.8	11
49	The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. Health Technology Assessment, 2016, 20, 1-64.	2.8	31
50	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76.	27.8	141
51	Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. American Heart Journal, 2015, 169, 17-24.e1.	2.7	25
52	A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. Health Technology Assessment, 2015, 19, 1-174.	2.8	55
53	Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients. Journal of the International AIDS Society, 2014, 17, 19498.	3.0	6
54	Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?. Lancet Infectious Diseases, The, 2014, 14, 650-655.	9.1	38

#	Article	IF	CITATIONS
55	Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. The Lancet Global Health, 2014, 2, e35-e43.	6.3	44
56	Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. Heart, 2013, 99, 873-881.	2.9	90
57	Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions. Value in Health, 2012, 15, 570-579.	0.3	101
58	Value for money and the Quality and Outcomes Framework in primary care in the UK NHS. British Journal of General Practice, 2010, 60, e213-e220.	1.4	61
59	Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ: British Medical Journal, 2008, 336, 251-254.	2.3	178
60	The role of NICE technology appraisal in NHS rationing. British Medical Bulletin, 2007, 81-82, 51-64.	6.9	35